7 Or 8 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.7)
-
Publication number: 20120172318Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.Type: ApplicationFiled: April 15, 2009Publication date: July 5, 2012Inventors: Krishna PERI, Felix POLYAK, William LUBELL, Eryk THOUIN, Sylvain CHEMTOB
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Publication number: 20120165250Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-I entry inhibitor candidate.Type: ApplicationFiled: June 24, 2010Publication date: June 28, 2012Inventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
-
Patent number: 8207132Abstract: Molecular targets and vaccines against them in the treatment of sea lice infection of fish are provided, particularly caligid copepods. Vaccines targeted to L. salmonis trypsin are shown to reduce the quantity of sea lice present in challenged salmon from day 14 p.i. onward. Additional and novel molecular targets for vaccines are also provided.Type: GrantFiled: July 28, 2005Date of Patent: June 26, 2012Assignee: National Research Council of CanadaInventors: Neil W. Ross, Stewart C. Johnson, Mark D. Fast, Kathryn Vanya Ewart
-
Patent number: 8207133Abstract: The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification of homeostasis, wherein said RS1 fragment is characterized in comprising at least 3 consecutive amino acid residues as comprised in the amino acid sequence S-D-S-D-R-I-E-P (Serine-Aspartic acid-Serine-Aspartic acid-Arginine-Isoleucine-Glutamic acid-Proline) (SEQ ID NO: 9) or derivatives thereof.Type: GrantFiled: March 31, 2006Date of Patent: June 26, 2012Assignee: Julius-Maximilians-Universitat WurzburgInventors: Herman Koepsell, Alexandra Vernaleken
-
Patent number: 8207128Abstract: Described is a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, a fusion protein thereof, a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. Described is also a pharmaceutical composition for the prevention or treatment of inflammatory diseases, or the inhibition of the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.Type: GrantFiled: September 20, 2006Date of Patent: June 26, 2012Assignee: Supadelixir Inc.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Dong-Min Kang
-
Publication number: 20120157372Abstract: The present invention provides for novel peptides derived from human milk In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations.Type: ApplicationFiled: June 1, 2010Publication date: June 21, 2012Inventors: Kenneth James Friel, Apollinaire Tsopmo
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Publication number: 20120142601Abstract: The invention includes compounds that are useful in treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain. The invention also includes methods for treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain in a subject in need thereof.Type: ApplicationFiled: July 20, 2011Publication date: June 7, 2012Inventors: George Walter Koszalka, Justin Orion Brower
-
Patent number: 8193154Abstract: Disclosed are peptides that inhibit the enzymatic activity of tyrosinase, as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Peptide sequences disclosed include KFEKKFEK (SEQ ID NO: 1) and YRSRKYSSWY (SEQ ID NO: 2).Type: GrantFiled: December 21, 2010Date of Patent: June 5, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Basil M. Hantash
-
Patent number: 8193155Abstract: A skin care composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; a method for inhibiting damage to human keratinocytes due to environmental aggressors by applying a composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; and a method for repairing DNA damage in human keratinocytes.Type: GrantFiled: February 9, 2009Date of Patent: June 5, 2012Assignee: ELC Management, LLCInventors: Daniel H. Maes, Nadine A. Pernodet, Lenny Slutsky, Donald F. Collins, Kerri Goldgraben, Edward Pelle, James Timothy McCarthy
-
Patent number: 8188050Abstract: The present invention concerns the use of peptide fragments of the protein SLC24A5 as active agents designed to induce, increase, or restore the synthesis of melanin in the melanocytes of the epidermis or of the pilar bulb, alone or in association with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical or particularly dermatological composition. The invention is also related to any composition containing the active agents.Type: GrantFiled: October 26, 2007Date of Patent: May 29, 2012Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8188222Abstract: [Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a higher therapeutic effect at a lower dose. [Means for Solving Problems] Disclosed is a high molecular weight derivative a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the nucleoside derivative is bound to the carboxyl group in the side chain of the high molecular weight compound via a highly hydrophobic linker.Type: GrantFiled: November 6, 2007Date of Patent: May 29, 2012Assignee: Nippon Kayaku Kabushiki KaishaInventors: Keiichiro Yamamoto, Kazutoshi Takashio
-
Publication number: 20120129791Abstract: The invention relates to a novel agent having an influence on the genital, sexual and reproductive function of mammals and human beings. More specifically, the invention relates to the use of a heptapeptide of the general formula (I) Thr-Lys-Pro-Arg-Pro-Gly-Pro as a stimulator of the genital, sexual and reproductive function of mammals and human beings. The invention widens the range of agents available for stimulating the genital, sexual and reproductive function of mammals and human beings.Type: ApplicationFiled: June 1, 2010Publication date: May 24, 2012Applicant: <<BIO PEPTID>> COMPANY LIMITEDInventors: Nikolay Fedorovich Myasoedov, Alim Vasilievich Nemersky, Mikhail Alexandrovich Mogutov, Tatiyana Nikolaevna Sollertinskaya, Mstislav Vladilenovich Shoroshov, Dmitry Viktorovich Golikov
-
Publication number: 20120128581Abstract: The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations.Type: ApplicationFiled: December 2, 2011Publication date: May 24, 2012Applicant: BRACCO SUISSE S.A.Inventors: Edmund C. Metcalfe, Jo Anna Monteferrante, Margaret Newborn, Irene Ropiak, Ernst Schramm, Gregory W. White, Julius P. Zodda
-
Publication number: 20120129776Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: ApplicationFiled: September 18, 2007Publication date: May 24, 2012Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Merav Beiman, Galit Rotman, Michal Ayalon-Soffer
-
Patent number: 8183211Abstract: A method for preventing or delaying the onset of autoimmune diseases is disclosed.Type: GrantFiled: August 5, 2009Date of Patent: May 22, 2012Assignee: University of Maryland, BaltimoreInventor: Alessio Fasano
-
Patent number: 8183043Abstract: A modified sol-gel material and method of making the same is provided herein. More particularly, sol-gels disclosed herein have been modified to have one or more bioactive peptides covalently bound to the surface of the sol-gel. In one embodiment the peptide presenting sol-gels are prepared as thin film coatings and in a further embodiment the sol-gels are combined with living cells. The present disclosure is also directed to a novel one vessel reaction process for preparing the sol-gel-based peptide material.Type: GrantFiled: October 11, 2007Date of Patent: May 22, 2012Assignee: Purdue Research FoundationInventors: Jenna Leigh Rickus, Sabrina S. Jedlicka
-
Publication number: 20120122790Abstract: The disclosure provides methods of treating X-linked hypophosphatemia, related bone demineralization and renal phosphate wasting disorders in a mammalian subject.Type: ApplicationFiled: October 13, 2011Publication date: May 17, 2012Inventors: Marc K. DREZNER, Baozhi Yuan
-
Publication number: 20120121675Abstract: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zs—R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, their preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases that are a consequence of muscle contraction.Type: ApplicationFiled: July 23, 2010Publication date: May 17, 2012Applicant: LIPOTEC, S.A.Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech, Gregorio Fernandez Ballester
-
Patent number: 8178497Abstract: Residual HIV-1 replication reemerges after intensive therapy from location or locations in the body called the drug resistant non-plasma viral reservoir. Methods are disclosed of treating HIV by inhibiting or blocking this reemergence with various monomeric therapeutic peptide compositions including monomeric DAPTA prepared in least 80% trifluoroethanol, with vigorous shaking for at least about 24 hours at about 37° C.Type: GrantFiled: November 14, 2007Date of Patent: May 15, 2012Assignee: Rapid Pharmaceuticals AGInventors: Michael Ruff, Candace Pert
-
Publication number: 20120114679Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.Type: ApplicationFiled: November 28, 2011Publication date: May 10, 2012Applicant: Nymox Pharmaceutical CorporationInventors: Paul Averback, Jack Gemmell
-
Publication number: 20120115797Abstract: Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein.Type: ApplicationFiled: November 4, 2011Publication date: May 10, 2012Inventor: Shanjana Awasthi
-
Publication number: 20120114628Abstract: The present invention relates to the use, especially the cosmetic and/or therapeutic use, of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof, of a nucleic acid sequence coding for such a polypeptide or of a modulator of the activity, stability or expression of such a polypeptide, especially for preventing and/or treating the signs of skin dryness. The invention also relates to the use of the protein DJ-1, of polypeptides derived from this protein or of analogues thereof or of a nucleic acid sequence coding for such a polypeptide, as a marker for evaluating the state of dryness of an epithelium.Type: ApplicationFiled: November 19, 2009Publication date: May 10, 2012Applicant: L'OREALInventors: Dominique Bernard, Lucie Simonetti, Isabelle Castiel
-
Publication number: 20120115789Abstract: The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS).Type: ApplicationFiled: May 26, 2010Publication date: May 10, 2012Inventors: Peter Nawroth, Angelika Bierhaus, Thomas Fleming
-
Publication number: 20120114759Abstract: Polymeric nanoparticles, microparticles, and gels for delivering cargo, e.g., a therapeutic agent, such as a peptide, to a target, e.g., a cell, and their use for treating diseases, including angiogenesis-dependent diseases, such as age-related macular degeneration and cancer, are disclosed. Methods for formulating, stabilizing, and administering single peptides or combinations of peptides via polymeric particle and gel delivery systems also are disclosed.Type: ApplicationFiled: October 12, 2011Publication date: May 10, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jordan Jamieson Green, Aleksander S. Popel, Joel Chaim Sunshine, Ron B. Shmueli, Stephany Yi Tzeng, Kristen Lynn Kozielski
-
Publication number: 20120114577Abstract: The present invention relates to a transforming growth factor-beta (TGF-?)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-?-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-? and improve drawbacks caused by high molecular weight of natural-occurring TGF-?. The peptide of this invention can be advantageously applied to treatment or improvement of TGF-?-effective disorders or conditions and have excellent efficacies on skin whitening and wrinkle improvement.Type: ApplicationFiled: April 14, 2009Publication date: May 10, 2012Applicant: CAREGEN CO., LTD.Inventors: Young Ji Chung, Young Deug Kim, Eun Mi Kim, Jeong Jin Choi, Jun Young Choi
-
Publication number: 20120108524Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.Type: ApplicationFiled: August 14, 2009Publication date: May 3, 2012Applicant: CIRCASSIA LIMITEDInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Patent number: 8168594Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.Type: GrantFiled: November 11, 2009Date of Patent: May 1, 2012Assignee: Alba Therapeutics CorporationInventors: Blake Paterson, Mark J. Ginski
-
Publication number: 20120094911Abstract: The present invention provides peptides capable of sustaining antagonist activity against substance P for long periods of time. A peptide selected from (a) to (d) can sustain antagonist activity against substance P, analgesic activity, and anti-inflammation activity for a long period of time: (a)?Ala-Tyr-Gln-Leu-Glu-His-Thr-DTrp-Gln-Gly-Leu- Leu-NH2; (b) a peptide consisting of a partial sequence of (a), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-DTrp-Gln-Gly-Leu-Leu-NH2; (c) Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-DTrp-Leu-Leu-NH2; and (d) a peptide consisting of a partial sequence of (e), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-Phe-Gln-DTrp-Leu-Leu-NH2.Type: ApplicationFiled: May 31, 2010Publication date: April 19, 2012Applicant: UNIVERSITY OF MIYAZAKIInventors: Toshikazu Nishimori, Rumi Naono
-
Publication number: 20120093919Abstract: The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided.Type: ApplicationFiled: October 14, 2011Publication date: April 19, 2012Applicants: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Joseph R. Bertino, Debabrata Banerjee, Tamara Minko, Olga B. Garbuzenko, Xiaoqi Xie, John E. Kerrigan, Emine E. Abali, Kathleen W. Scotto
-
Patent number: 8158586Abstract: Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders.Type: GrantFiled: April 11, 2006Date of Patent: April 17, 2012Assignee: Pharmagap Inc.Inventors: Raphael Terreux, Jenny Phipps
-
Publication number: 20120082731Abstract: Disclosed herein are methods comprising suspending microparticles in a surfactant/non-polar alkane solution to remove residual solvent that is present in the microparticle.Type: ApplicationFiled: September 28, 2011Publication date: April 5, 2012Inventors: Adrian Raiche, Brenda Perkins
-
Patent number: 8148322Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.Type: GrantFiled: December 4, 2009Date of Patent: April 3, 2012Assignee: Cornell Research Foundation, Inc.Inventors: Hazel Szeto, Kesheng Zhao, Hugh Robertson, Alex Birk
-
Publication number: 20120076861Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.Type: ApplicationFiled: August 22, 2011Publication date: March 29, 2012Applicants: University of Maryland, Baltimore, Alba Therapeutics CorporationInventors: Alessio FASANO, Blake Paterson
-
Patent number: 8143221Abstract: This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.Type: GrantFiled: October 3, 2008Date of Patent: March 27, 2012Assignees: Ramot at Tel-Aviv University, Allon Therapeutics, inc.Inventors: Illana Gozes, James Miller
-
Publication number: 20120071399Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.Type: ApplicationFiled: June 28, 2011Publication date: March 22, 2012Applicant: ENZO BIOCHEM, INC.Inventors: JOSHUA RABBANI, JAMES J. DONEGAN, XIAOFENG LI
-
Publication number: 20120065131Abstract: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment.Type: ApplicationFiled: August 29, 2011Publication date: March 15, 2012Applicant: Revance Therapeutics, Inc.Inventors: Michael D. Dake, Jacob M. Waugh
-
Publication number: 20120058957Abstract: Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compounds may be used as components of pharmaceuticals and dietary supplements.Type: ApplicationFiled: August 26, 2011Publication date: March 8, 2012Applicant: Ischemix, Inc.Inventor: Victor E. Shashoua
-
Publication number: 20120058933Abstract: The present invention provides Parotid Secretory Protein peptides, nucleic acids encoding the peptides, and methods of using the peptides, and methods of screening GL13 mimetics.Type: ApplicationFiled: May 8, 2008Publication date: March 8, 2012Applicant: University of Louisville Research FoundationInventor: Sven-Ulrik Gorr
-
Publication number: 20120045394Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.Type: ApplicationFiled: November 1, 2011Publication date: February 23, 2012Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Wadih Arap, Renata Pasqualini
-
Publication number: 20120040915Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.Type: ApplicationFiled: August 1, 2011Publication date: February 16, 2012Inventors: Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
-
Publication number: 20120040918Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.Type: ApplicationFiled: March 13, 2009Publication date: February 16, 2012Applicant: CTI BIOInventors: Jong-Ook Lee, Shin Chung, Heui-Yeon Kim, Hyun-Jin Park, Mi-Ran Kim
-
Publication number: 20120039801Abstract: Disclosed are SPARC and albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents In particular, compositions comprising SPARC binding peptide—Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: ApplicationFiled: December 7, 2009Publication date: February 16, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 8114844Abstract: Linear and cyclic peptidomimetics which bind to one or more melanocortin receptors are provided, which peptidomimetics include at least one ring-constrained amino acid surrogate of formula I: where R1, R2, R3, R4, R5, R6, R7, R8, and y are as defined in the specification, together with methods for synthesizing ring-constrained amino acid surrogates of formula I and peptidomimetics incorporating the same, and methods of use of peptidomimetics in the treatment of various diseases, syndromes and conditions.Type: GrantFiled: October 3, 2008Date of Patent: February 14, 2012Assignee: Palatin Technologies, Inc.Inventors: Shubh D. Sharma, Margarita Bastos, Wei Yang
-
Publication number: 20120035117Abstract: This invention relates a process for preparing octreotide and derivatives thereof. The starting material, Cys(Trt)-2-Chlorotrityl resin is coupled with various amino acids to obtain a protected heptapeptide of formula (2): Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-2-Chlorotrityl resin. The linear protected peptide of formula (2) is cleaved from the support using TFA5TIS and water to yield linear protected peptide of formula (3) Boc-D-Phe-Cys(Trt)-Phe-D-Trp-Lys(Boc)-Thr(OBut)-Cys(Trt)-OH Linear protected heptapeptide of formula (3) is deprotected to yield heptapeptide of formula (6): D-Phe-Cys-Phe-D-Tip-Lys-Thr-Cys-OH; which is cyclized using hydrogen peroxide and to the cyclic peptide of formula (7) D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-OH; threoninol is coupled at C terminal to yield octreotide.Type: ApplicationFiled: May 4, 2009Publication date: February 9, 2012Inventors: Divya Lal Saksena, Digamber Shripati Pawar, Nikhil Umesh Mohe, Nilesh Dagdu Patil, Chandrakesan Muralidharan, Lester Lobo, Radhakrishnan Venkatasubramanian Tarur
-
Publication number: 20120027879Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 3, 2011Publication date: February 2, 2012Inventor: Harry A. DUGGER, III
-
Publication number: 20120028888Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.Type: ApplicationFiled: November 4, 2009Publication date: February 2, 2012Inventors: Jay Janz, Athan Kuliopulos, Thomas J. McMurry
-
Publication number: 20120028912Abstract: The present invention features compounds useful for and methods for preventing or inhibiting the binding of bromodomains to acetyl-lysine residues of proteins and methods for treating HIV infection and HIV related disease.Type: ApplicationFiled: November 2, 2009Publication date: February 2, 2012Inventors: Ming-Ming Zhou, Aneel K. Aggarwal, Melanie Ott, Eric Verdin
-
Publication number: 20120027720Abstract: The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide conjugate of the invention, optionally.Type: ApplicationFiled: June 24, 2011Publication date: February 2, 2012Inventors: Amir TAMIZ, Sefik Alkan